| 1 |
NCT01172717 |
Withdrawn |
Study of Panitumumab in the Treatment of Carcinoid Syndrome |
|
|
Interventional |
Phase 2 |
- Boston Medical Center
- Amgen
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Radiographic measures
- Tumor Marker Evaluations
- Quality of LIfe
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01172717 |
H-31701 |
|
July 2013 |
July 2013 |
July 2013 |
July 30, 2010 |
July 26, 2013 |
|
- Boston Medical Center
Boston, Massachusetts, United States - Lahey Clinic
Burlington, Massachusetts, United States
|
| 2 |
NCT01104415 |
Completed
Has Results |
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome |
- Symptoms of Carcinoid Syndrome
|
- Drug: Low Dose LX1606 - Day 1 (start)
- Drug: Mid-low dose LX1606 - Day 15 (start)
- Drug: Mid-high dose LX1606 - Day 29 (start)
- Drug: High dose LX1606 - Day 43 (start)
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Any Drug-related Treatment-emergent Adverse Event
- Change in Number of Bowel Movements
- Change in Weekly Stool Form
- (and 12 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01104415 |
Protocol LX1606.1-203-CS
LX1606.203, LX1032
2013-002596-18 |
|
May 2010 |
February 2014 |
February 12, 2014 |
April 15, 2010 |
April 6, 2018 |
April 6, 2018 |
- Lexicon Investigational Site
Bad Berka, Germany - Lexicon Investigational Site
Berlin, Germany - Lexicon Investigational Site
Halle, Germany - (and 7 more...)
|
| 3 |
NCT02063659 |
Completed
Has Results |
Telotristat Etiprate for Carcinoid Syndrome Therapy |
|
- Drug: Telotristat etiprate
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period
- Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension Period
- (and 6 more...)
|
76 |
All |
18 Years and older (Adult, Senior) |
NCT02063659 |
LX1606.1-303-CS
LX1606.303
2013-001543-31 |
TELECAST |
March 11, 2014 |
March 29, 2016 |
March 29, 2016 |
February 14, 2014 |
February 26, 2018 |
September 25, 2017 |
- Lexicon Investigational Site
Stanford, California, United States - Lexicon Investigational Site
Orlando, Florida, United States - Lexicon Investigational Site
Iowa City, Iowa, United States - (and 47 more...)
|
| 4 |
NCT01430871 |
Completed |
Effects of Serotonin Excess on Bone in Carcinoid Syndrome |
|
|
Observational |
|
- Sheffield Teaching Hospitals NHS Foundation Trust
- University of Sheffield
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Lumbar spine and total hip Bone Mineral Density BMD) measured by Dual-emission X-ray absorptiometry (DXA)
- Self-reported fracture history
- Vertebral fracture assessment
- (and 7 more...)
|
52 |
All |
18 Years and older (Adult, Senior) |
NCT01430871 |
STH15805 |
|
January 2011 |
November 2011 |
November 2011 |
September 8, 2011 |
June 15, 2012 |
|
- Academic Unit of Bone Metabolism (Sheffield)
Sheffield, South Yorks, United Kingdom
|
| 5 |
NCT01677910 |
Completed
Has Results |
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) |
|
- Drug: Telotristat etiprate
- Drug: Placebo-matching telotristat etiprate
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period
- Number of Participants With TEAEs in the Open-Label Extension Period
- (and 3 more...)
|
135 |
All |
18 Years and older (Adult, Senior) |
NCT01677910 |
LX1606.1-301-CS
LX1606.301
2012-003460-47 |
|
January 8, 2013 |
March 21, 2016 |
March 21, 2016 |
September 3, 2012 |
February 27, 2018 |
September 18, 2017 |
- Lexicon Investigational Site
Mobile, Alabama, United States - Lexicon Investigational Site
Palo Alto, California, United States - Lexicon Investigational Site
San Francisco, California, United States - (and 72 more...)
|
| 6 |
NCT01018953 |
Terminated
Has Results |
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Patients With a Positive Overall Satisfactory Relief of Symptoms (Diarrhoea and/or Flushes) on the Likert Scale
- Percentage of Patients With Improvement in Symptoms (Diarrhoea and/or Flushes)
- Change in the Quality of Life (QoL) Assessment
- (and 4 more...)
|
8 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01018953 |
8-55-52060-004 |
CAMPANULA |
February 2010 |
December 2010 |
January 2011 |
November 25, 2009 |
September 7, 2015 |
September 7, 2015 |
- University Hospital, Internal Medicine - Oncology
Vienna, Austria - UZ Antwerpen
Edegem, Belgium - UZ Gent
Gent, Belgium - (and 51 more...)
|
| 7 |
NCT00884715 |
Terminated |
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess the effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea
- safety and tolerability of the implants
|
10 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00884715 |
IP107-002 |
|
July 2009 |
November 2011 |
December 2011 |
April 21, 2009 |
September 20, 2013 |
|
- Iowa, Iowa, United States
- Boston, Massachusetts, United States
- Burlington, Massachusetts, United States
|
| 8 |
NCT00092287 |
Terminated |
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome |
- Malignant Carcinoid Syndrome
|
- Drug: lanreotide Autogel (somatostatin analogue)
- Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Target symptom frequency (flushing or stool frequency).
|
196 |
All |
18 Years and older (Adult, Senior) |
NCT00092287 |
2-47-52030-722 |
|
July 2004 |
|
October 2004 |
September 27, 2004 |
February 27, 2008 |
|
- Larry Kvols, MD
Tampa, Florida, United States
|
| 9 |
NCT00774930 |
Completed
Has Results |
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome |
|
- Drug: Lanreotide
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Days With Subcutaneous Octreotide as Rescue Medication
- Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.
- Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.
- (and 7 more...)
|
115 |
All |
18 Years and older (Adult, Senior) |
NCT00774930 |
2-55-52030-730
TR321
2010-019066-92 |
ELECT |
May 2009 |
May 2013 |
December 2015 |
October 17, 2008 |
February 14, 2017 |
February 9, 2016 |
- VA Greater Los Angeles Health Care System
Los Angeles, California, United States - David Geffen School of Medicine at UCLA
Los Angeles, California, United States - Stanford Cancer Center
Stanford, California, United States - (and 51 more...)
|
| 10 |
NCT02026063 |
Active, not recruiting |
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms |
|
- Drug: Telotristat etiprate tablets (250 mg)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events
- Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQC30 Score at Each Visit
- Change From Baseline in Gastrointestinal Symptoms of Carcinoid Neuroendocrine Tumors (GI.NET21) Score at Each Visit
- (and 2 more...)
|
71 |
All |
18 Years and older (Adult, Senior) |
NCT02026063 |
LX1606.1-302-CS
LX1606.302 |
TELEPATH |
January 14, 2014 |
June 2018 |
|
January 1, 2014 |
July 14, 2017 |
|
- Lexicon Investigational Site
Mobile, Alabama, United States - Lexicon Investigational Site
Stanford, California, United States - Lexicon Investigational Site
Iowa City, Iowa, United States - (and 40 more...)
|
| 11 |
NCT00853047 |
Completed |
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy |
|
- Drug: Low Dose LX1606 Part 1
- Drug: Mid-Low Dose LX1606 Part 1
- Drug: Mid-High Dose LX1606 Part 1
- (and 6 more...)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety (physical examinations, clinical laboratory tests, vitals signs measurements, and ECGs)
- Symptom diary
- Effectiveness (number of bowel movements compared to baseline)
- (and 4 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT00853047 |
Protocol LX1606.1-202-CS
LX1606.202
LX1032 |
|
March 2009 |
June 2014 |
June 2014 |
February 27, 2009 |
May 3, 2016 |
|
- Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - St. Francis Medical Group Oncology and Hematology Specialists
Indianapolis, Indiana, United States - (and 6 more...)
|
| 12 |
NCT01234168 |
Completed |
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea |
- Neuroendocrine Tumors
- Carcinoid Syndrome
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Subject's overall satisfaction regarding control of diarrhea
- Impact on daily activities of the clinical manifestations of diarrhea
|
340 |
All |
18 Years and older (Adult, Senior) |
NCT01234168 |
8-79-52030-736 |
SYMNET |
October 2010 |
December 2012 |
December 2012 |
November 4, 2010 |
February 1, 2017 |
|
- Teaching Hospital Brno Bohunice
Brno, Czech Republic - University Hospital Hradec Kralove
Hradec Kralove, Czech Republic - Hospital Pardubice
Pardubice, Czech Republic - (and 54 more...)
|
| 13 |
NCT03223428 |
Recruiting |
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of patients who are satisfied with their overall symptom control
- Proportion of patients reporting satisfaction of CS-related diarrhea control
- Proportion of patients reporting satisfaction of CS- related flushing control
- (and 6 more...)
|
643 |
All |
18 Years and older (Adult, Senior) |
NCT03223428 |
LX1606.1-401-CS
LX1606.401 |
RELAX |
June 22, 2017 |
December 2021 |
December 2021 |
July 21, 2017 |
July 21, 2017 |
|
- RTI-HS
Research Triangle Park, North Carolina, United States
|
| 14 |
NCT01932528 |
Completed |
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males |
|
- Drug: 500 mg [14C]-LX1606
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum plasma concentration of LX1606 and LX1033
- Time to maximum plasma concentration of and LX1033
- Determination of total radioactivity in blood and plasma
- (and 4 more...)
|
8 |
Male |
30 Years to 65 Years (Adult) |
NCT01932528 |
LX1606.1-104-NRM |
LX1606-104 |
August 2013 |
September 2013 |
|
August 30, 2013 |
October 23, 2013 |
|
- Lexicon Investigational Site
Nottingham, United Kingdom
|
| 15 |
NCT03220087 |
Recruiting |
Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- Use of resources and costs in patients with controlled or uncontrolled CS
- Clinical characteristics and therapeutic management of patients with NET and controlled or uncontrolled CS
- Relationship between the state of health perceived by the patient and the clinical status of the disease reported by the physician.
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT03220087 |
A-ES-52030-367 |
RECOSY |
July 21, 2017 |
March 28, 2018 |
March 28, 2018 |
July 18, 2017 |
February 27, 2018 |
|
- Hospital General Univ. de Elche
Alicante, Spain - ICO Badalona
Badalona, Spain - Hospital Clínico y Provincial de Barcelona
Barcelona, Spain - (and 25 more...)
|
| 16 |
NCT01886287 |
Terminated
Has Results |
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome |
|
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Improved Frequency of Diarrhea
- Rate of Progression Free Survival (PFS) at 6 Months
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT01886287 |
MCC-17410
CSMS995AUS64T |
|
December 2013 |
August 2014 |
October 2014 |
June 25, 2013 |
January 12, 2015 |
January 12, 2015 |
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
| 17 |
NCT03453489 |
Not yet recruiting |
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm |
- Carcinoid Syndrome
- Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
|
- Other: Carbon C 11 Alpha-methyltryptophan
- Other: Laboratory Biomarker Analysis
- Procedure: Positron Emission Tomography
- Drug: Telotristat Etiprate
|
Interventional |
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of patients who achieved maximum standardized uptake value (SUVmax) reduction of 20% or more
- Change in mean standardized uptake value (SUVmean)
- Neuroendocrine tumors visibility
- (and 2 more...)
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT03453489 |
2017-144
NCI-2018-00294
P30CA022453 |
|
April 30, 2018 |
January 1, 2019 |
January 1, 2019 |
March 5, 2018 |
April 12, 2018 |
|
- Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
|
| 18 |
NCT00955604 |
Completed |
Azilect + Antidepressant Chart Review |
|
- Drug: Group R+AD Rasagiline + Antidepressant
- Drug: Group R Rasagiline
- Drug: Group AD Anti-PD + Antidepressant
|
Observational |
|
- Teva Pharmaceutical Industries
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- The frequency of serotonin toxicity, as determined by the Adjudication Committee will be calculated for each Group. The primary comparison will be Group R+AD vs. Group R and vs. Group AD
|
1500 |
All |
Child, Adult, Senior |
NCT00955604 |
TVP-1012/PM102 CR |
STACCATO |
July 2009 |
March 2010 |
June 2010 |
August 10, 2009 |
February 6, 2017 |
|
|
| 19 |
NCT00412061 |
Completed
Has Results |
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor |
- Carcinoid Tumor
- Malignant Carcinoid Syndrome
|
- Drug: Octreotide
- Drug: Placebo
- Drug: Everolimus
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review
- Best Overall Response Rate as Per Adjudicated Central Radiology Review Based on Response Evaluation Criteria in Solid Tumors (RECIST)
- Progression Free Survival (PFS) as Per Adjudicated Central Review by Baseline 5-hydroxyindoleacetic Acid (5-HIAA) Level
- (and 4 more...)
|
429 |
All |
18 Years and older (Adult, Senior) |
NCT00412061 |
CRAD001C2325
2006-004507-18 |
RADIANT-2 |
December 2006 |
April 2010 |
June 2013 |
December 15, 2006 |
November 21, 2014 |
March 12, 2012 |
- University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2)
Tucson, Arizona, United States - Highlands Oncology Group The Center for Chest Care
Fayetteville, Arkansas, United States - Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States - (and 67 more...)
|
| 20 |
NCT00002470 |
Completed |
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors |
- Gastrointestinal Carcinoid Tumor
- Lung Cancer
|
- Biological: recombinant interferon alfa
- Drug: fluorouracil
|
Interventional |
Phase 2 |
- Mid-Atlantic Oncology Program
- Cancer Biotherapy Research Group
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00002470 |
MAOP-5190
CDR0000076667
NBSG-9010
NCI-V90-0197 |
|
September 1990 |
|
January 2004 |
January 27, 2003 |
May 15, 2013 |
|
- George Washington University Medical Center
Washington, District of Columbia, United States
|
| 21 |
NCT00055809 |
Completed |
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors |
- Metastatic Gastrointestinal Carcinoid Tumor
- Recurrent Gastrointestinal Carcinoid Tumor
- Regional Gastrointestinal Carcinoid Tumor
|
- Biological: PEG-interferon alfa-2b
- Biological: bevacizumab
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response rate (CR + PR) as measured by RECIST criteria
- Progression free survival
- Biochemical response rate measured after treatment
- Toxicity graded according to CTC v3.0 criteria for adverse outcomes
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT00055809 |
NCI-2012-02519
MDA-ID-02063
N01CM62202
CDR0000271225 |
|
January 2003 |
June 2007 |
|
March 7, 2003 |
January 23, 2013 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
| 22 |
NCT00088595 |
Completed
Has Results |
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors |
|
- Drug: Pasireotide (SOM230)
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary
- Duration of Complete Symptom Control (Days) by Dose Class
- Duration of Partial Symptom Control (Days) by Dose Class
- (and 2 more...)
|
45 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00088595 |
CSOM230B2202 |
|
January 2004 |
July 2008 |
July 2008 |
August 2, 2004 |
June 4, 2012 |
May 6, 2011 |
- Cedars-Sinai Medical Center
Los Angeles, California, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - Univ. Of Iowa Holden Cancer Center
Iowa City, Iowa, United States - Louisiana State University Medical Center
New Orleans, Louisiana, United States
|
| 23 |
NCT01841736 |
Active, not recruiting |
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors |
- Atypical Carcinoid Tumor
- Foregut Carcinoid Tumor
- Hindgut Carcinoid Tumor
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Pazopanib Hydrochloride
- Other: Placebo
- Other: Quality-of-Life Assessment
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival
- Objective response rate, defined as the percentage of patients with a confirmed complete response or partial response per Response Evaluation Criteria in Solid Tumors 1.1 criteria
- Overall survival
- (and 3 more...)
|
165 |
All |
18 Years and older (Adult, Senior) |
NCT01841736 |
NCI-2013-00831
ALLIANCE A021202
CALGB-A021202
A021202
U10CA180821
U10CA180830
U10CA031946 |
|
June 21, 2013 |
July 15, 2018 |
|
April 26, 2013 |
April 13, 2018 |
|
- Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - Anchorage Oncology Centre
Anchorage, Alaska, United States - (and 432 more...)
|
| 24 |
NCT00416767 |
Completed |
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Neoplastic Syndrome
|
- Drug: fluorouracil
- Drug: irinotecan hydrochloride
- Drug: leucovorin calcium
|
Interventional |
Phase 2 |
- Federation Francophone de Cancerologie Digestive
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
20 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00416767 |
CDR0000453858
FFCD-0302
EU-20544
PFIZER-FFCD-0302 |
|
May 2004 |
January 2006 |
July 2007 |
December 28, 2006 |
May 30, 2016 |
|
|
| 25 |
NCT00227773 |
Withdrawn |
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Carcinoma
|
- Drug: octreotide acetate
- Drug: vatalanib
- Procedure: anti-cytokine therapy
- (and 8 more...)
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
0 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00227773 |
CDR0000446076
ECOG-E6203 |
|
|
|
|
September 28, 2005 |
October 8, 2015 |
|
|
| 26 |
NCT00789841 |
Completed |
Gastrointestinal Motility in Patients With Neuroendocrine Tumors |
|
- Device: Magnetic Tracking System (MTS) and radio-opaque markers
|
Observational |
|
- University of Aarhus
- Novartis
- The Danish Medical Research Council
|
Other / Industry |
|
- Gastrointestinal transit time in NET patients
- Gastric emptying in NET patients
- Small intestinal transit time
- (and 2 more...)
|
13 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT00789841 |
M-20080121 |
|
September 2008 |
May 2010 |
May 2010 |
November 13, 2008 |
October 26, 2010 |
|
- Analfysiologisk afsnit, Aarhus University Hospital, Tage Hansensgade, entrance 11A
Aarhus, Denmark
|
| 27 |
NCT01371045 |
Unknown † |
Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs |
|
- Other: Oral Glucose Tolerance Test (OGTT)
|
Observational |
|
- Cedars-Sinai Medical Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Growth hormone response to OGTT
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT01371045 |
Pro00024880 |
|
June 2011 |
|
|
June 10, 2011 |
June 10, 2011 |
|
- Cedars-Sinai Medical Center, Pituitary Center
Los Angeles, California, United States
|
| 28 |
NCT00730483 |
Terminated
Has Results |
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Metastatic Cancer
|
- Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
|
Interventional |
Not Applicable |
- Yale University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE
- Tumor Response (Efficacy) - by Response Evaluation Criteria in Solid Tumors (RECIST) and the European Association for the Study of the Liver (EASL) Criteria
- Survival
- (and 2 more...)
|
13 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00730483 |
J0739 CDR0000601054
JHOC-J7039
JHOC-NA_000010736
JHOC-SKCCC-J7039 |
|
February 2009 |
June 2014 |
June 2014 |
August 8, 2008 |
August 25, 2017 |
August 25, 2017 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 29 |
NCT00602082 |
Completed |
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
|
- Drug: capecitabine
- Drug: cisplatin
- Drug: streptozocin
- (and 5 more...)
|
Interventional |
Phase 2 |
- Cambridge University Hospitals NHS Foundation Trust
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
- Objective response rate
- Overall response rate
- Functional response
- (and 5 more...)
|
84 |
All |
18 Years and older (Adult, Senior) |
NCT00602082 |
CRCA-CCTC-NET-01
CDR0000582315
EUDRACT-2004-005202-71
EU-207102
ISRCTN35124268 |
|
August 2005 |
December 2009 |
December 2009 |
January 28, 2008 |
August 7, 2013 |
|
- Basildon University Hospital
Basildon, England, United Kingdom - Addenbrooke's Hospital
Cambridge, England, United Kingdom - Cookridge Hospital
Leeds, England, United Kingdom - (and 14 more...)
|
| 30 |
NCT00427349 |
Completed
Has Results |
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Neoplastic Syndrome
|
- Drug: AMG 706
- Drug: octreotide
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Four-month Progression-free Survival Rate
- Overall Survival
- Objective Response Rate
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00427349 |
CDR0000526256
ECOG-E4206
U10CA023318 |
|
September 2008 |
October 2014 |
April 2015 |
January 29, 2007 |
August 12, 2016 |
June 4, 2015 |
- Hematology Oncology Associates of Illinois - Berwyn
Berwyn, Illinois, United States - Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States - Hematology and Oncology Associates
Chicago, Illinois, United States - (and 109 more...)
|
| 31 |
NCT00227617 |
Unknown † |
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Lung Cancer
- (and 2 more...)
|
- Biological: bevacizumab
- Drug: 5-fluorouracil
- Drug: leucovorin
- Drug: oxaliplatin
|
Interventional |
Phase 2
Phase 3 |
- University of California, San Francisco
- National Cancer Institute (NCI)
- Genentech, Inc.
- Sanofi
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The rate of discontinuation due to adverse events (besides neuropathy) possibly related to study treatment.
- Objective radiographic response rate
- Overall survival
- (and 3 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT00227617 |
04458
P30CA082103
UCSF-04458 |
|
June 2005 |
January 2012 |
June 2016 |
September 28, 2005 |
April 9, 2015 |
|
- UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - Kaiser Permanente Medical Center - Vallejo
Vallejo, California, United States
|
| 32 |
NCT00093782 |
Completed
Has Results |
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma |
- Metastatic Gastrointestinal Carcinoid Tumor
- Pulmonary Carcinoid Tumor
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Islet Cell Carcinoma
|
- Drug: temsirolimus
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria)
- Stable Disease Rate Defined by RECIST Criteria
- Median Survival Time
- (and 4 more...)
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT00093782 |
NCI-2012-03053
PHL-021
6171
N01CM17105
N01CM17107
N01CM17102 |
|
December 2003 |
April 2011 |
April 2011 |
October 8, 2004 |
February 7, 2017 |
December 12, 2016 |
- Princess Margaret Hospital Phase 2 Consortium
Toronto, Ontario, Canada
|
| 33 |
NCT00017199 |
Completed |
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
|
|
Interventional |
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00017199 |
CDR0000068660
OSU-00H0328
NCI-1856 |
|
April 2001 |
|
May 2007 |
February 16, 2004 |
January 31, 2013 |
|
- University of Chicago Cancer Research Center
Chicago, Illinois, United States - Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States
|
| 34 |
NCT00027638 |
Completed |
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Lung Cancer
- Neoplastic Syndrome
|
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
Child, Adult, Senior |
NCT00027638 |
MSKCC-01027
CDR0000069051
NCI-G01-2029 |
|
March 2001 |
December 2003 |
December 2003 |
January 27, 2003 |
June 18, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
| 35 |
NCT02299089 |
Completed
Has Results |
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) |
- Acromegaly
- Neuroendocrine Tumors
|
- Drug: octreotide FluidCrystal® injection depot
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC
- Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC.
- Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Ctrough
- (and 5 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT02299089 |
HS-12-455 |
|
January 2015 |
May 2016 |
June 2016 |
November 24, 2014 |
December 15, 2017 |
December 15, 2017 |
- Hospices Civils de Lyon
Bron, France - CHU Rouen, Hôpital Charles Nicolle
Rouen cedex, France - Abteilung: Klinische Studien
Bad Berka, Germany - (and 7 more...)
|
| 36 |
NCT03375320 |
Not yet recruiting |
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery |
- Atypical Carcinoid Tumor
- Carcinoid Tumor
- Digestive System Neuroendocrine Neoplasm
- (and 13 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Placebo
- Other: Quality-of-Life Assessment
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by independent central review
- Overall survival (OS)
- Incidence of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- Radiographic response rate defined as the proportion of patients in each arm whose best response is either complete response (CR) or partial response (PR)
|
395 |
All |
18 Years and older (Adult, Senior) |
NCT03375320 |
NCI-2017-02297
A021602
U10CA180821 |
|
June 12, 2018 |
January 1, 2021 |
January 1, 2021 |
December 18, 2017 |
March 13, 2018 |
|
- Alliance for Clinical Trials in Oncology
Boston, Massachusetts, United States
|
| 37 |
NCT02259725 |
Recruiting |
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 6 more...)
|
- Drug: regorafenib
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Tumor response rate, evaluated using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee
- Overall survival
- Incidence of adverse events, assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT02259725 |
0S-14-3
NCI-2014-01996
HS-14-00583
P30CA014089 |
|
August 16, 2016 |
August 16, 2019 |
August 16, 2020 |
October 8, 2014 |
April 20, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - USC Norris Comprehensive Cancer Center
Los Angeles, California, United States - Seattle Cancer Care Alliance
Seattle, Washington, United States
|
| 38 |
NCT01548482 |
Completed |
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
- Adult Solid Neoplasm
- Lung Carcinoid Tumor
- Recurrent Digestive System Neuroendocrine Tumor G1
- (and 8 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Temsirolimus
- Biological: Trebananib
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RP2D of trebananib and temsirolimus defined as the dose level at which =< 1/6 patients experienced dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) CTCAE version 4.0
- Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0
- Objective response to treatment assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
- PD effects of both drugs when administered in combination
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT01548482 |
NCI-2012-02848
CDR0000728823
PJC-008
9041
U01CA132123
UM1CA186644 |
|
March 2012 |
January 2014 |
January 2014 |
March 8, 2012 |
October 6, 2015 |
|
- BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada - Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
| 39 |
NCT00131911 |
Completed
Has Results |
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 7 more...)
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed Response Rate
- Toxicity
- Overall Survival
- (and 2 more...)
|
93 |
All |
18 Years and older (Adult, Senior) |
NCT00131911 |
NCI-2009-00121
MC044H
7046
CDR0000437792
N01CM62205 |
|
June 2005 |
October 2010 |
April 2013 |
August 19, 2005 |
November 17, 2014 |
November 17, 2014 |
- Mayo Clinic
Rochester, Minnesota, United States
|
| 40 |
NCT01204476 |
Completed |
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
- Gastrin-Producing Neuroendocrine Tumor
- Lung Carcinoid Tumor
- Metastatic Digestive System Neuroendocrine Tumor G1
- (and 12 more...)
|
- Biological: Cixutumumab
- Drug: Everolimus
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLTs) for the combination of cixutumumab and everolimus with octreotide acetate
- Pharmacodynamic markers in blood and tumor tissue
- Pharmacokinetic parameters
- (and 2 more...)
|
27 |
All |
18 Years and older (Adult, Senior) |
NCT01204476 |
NCI-2010-02196
CDR0000685267
2009-0734
8354
P30CA016672
U01CA062461 |
|
October 2010 |
July 2014 |
|
September 17, 2010 |
July 15, 2016 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
| 41 |
NCT01155258 |
Completed |
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors |
- Extensive Stage Small Cell Lung Cancer
- Hereditary Paraganglioma
- Male Breast Cancer
- (and 45 more...)
|
- Drug: temsirolimus
- Drug: vinorelbine ditartrate
|
Interventional |
Phase 1 |
- University of Southern California
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximum tolerated dose of Temsirolimus and Vinorelbine
- To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST)
- To evaluate the safety and tolerability of Temsirolimus and Vinorelbine
- Progression-free and overall survival
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT01155258 |
0C-09-6
NCI-2010-01382 |
|
June 2010 |
January 2013 |
May 2014 |
July 1, 2010 |
June 13, 2016 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
| 42 |
NCT01048892 |
Completed |
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features |
- Adrenocortical Carcinoma
- Gastrointestinal Carcinoid Tumor
- Kidney Cancer
- (and 3 more...)
|
- Biological: Seneca Valley virus-001
- Drug: cyclophosphamide
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional |
Phase 1 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability
- Recommended phase II dose of Seneca Valley virus-001 (NTX-010)
- Tumor response
- (and 2 more...)
|
22 |
All |
3 Years to 21 Years (Child, Adult) |
NCT01048892 |
ADVL0911
COG-ADVL0911
CDR0000663520 |
|
September 2009 |
June 2013 |
|
January 14, 2010 |
January 30, 2014 |
|
- UAB Comprehensive Cancer Center
Birmingham, Alabama, United States - Children's Hospital of Orange County
Orange, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 15 more...)
|
| 43 |
NCT00454376 |
Unknown † |
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors |
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Lung Cancer
- (and 2 more...)
|
- Other: questionnaire administration
- Procedure: quality-of-life assessment
|
Observational |
|
- National Cancer Institute (NCI)
|
NIH |
|
- Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)
- Response to change after various treatments
|
408 |
All |
18 Years and older (Adult, Senior) |
NCT00454376 |
CDR0000537344
EORTC-QLQ-G.I.NET21
EU-20712
BNHFT-P4NET
EU-207101 |
|
October 2006 |
|
|
March 30, 2007 |
October 29, 2013 |
|
- Aarhus Universitetshospital - Aarhus Sygehus
Aarhus, Denmark - Charite - Campus Charite Mitte
Berlin, Germany - Klinikum der Universitaet Regensburg
Regensburg, Germany - (and 13 more...)
|
| 44 |
NCT01010126 |
Completed |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
- Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
- Endometrial Serous Adenocarcinoma
- (and 42 more...)
|
- Biological: Bevacizumab
- Drug: Temsirolimus
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival rate, defined as the proportion of efficacy-evaluable patients on study without documentation of disease progression 6 months from registration
- Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study
- Duration of response
- (and 4 more...)
|
252 |
All |
18 Years and older (Adult, Senior) |
NCT01010126 |
NCI-2012-02086
NCI-2011-02504
MC0845
CDR0000653790
NCI-2012-01049
8233
N01CM00032
N01CM00038
N01CM00039
N01CM00070
N01CM00071
N01CM00099
N01CM00100
N01CM62201
N01CM62203
N01CM62204
N01CM62205
N01CM62206
N01CM62207
N01CM62208
N01CM62209
P30CA015083
P50CA102701 |
|
September 8, 2009 |
March 13, 2017 |
March 13, 2017 |
November 9, 2009 |
July 11, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Tower Cancer Research Foundation
Beverly Hills, California, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 58 more...)
|
| 45 |
NCT00084461 |
Terminated |
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 7 more...)
|
- Drug: romidepsin
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Incidence of toxicity
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00084461 |
NCI-2012-01449
0425
NCI-6325
OSU-2003C0085
CDR0000365313
U01CA076576 |
|
March 2004 |
October 2004 |
|
June 11, 2004 |
June 4, 2013 |
|
- Ohio State University Medical Center
Columbus, Ohio, United States
|
| 46 |
NCT00903396 |
Terminated
Has Results |
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer |
- Anal Cancer
- Carcinoma of the Appendix
- Colorectal Cancer
- (and 9 more...)
|
- Drug: palonosetron hydrochloride
- Other: placebo
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Complete Response (no Episodes of Nausea or Vomiting)
- Time to Treatment Failure, Defined as a Single Episode of Vomiting, Daily Nausea Score of Moderate or Greater, or Taking ≥ 3 Prochlorperazine or Haloperidol Tablets Per Day
- Proportion of Patients Reporting Treatment Failure
- (and 2 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT00903396 |
NCCTG-N08C2
NCI-2009-01109
CDR0000642449 |
|
September 2009 |
January 2011 |
May 2013 |
May 18, 2009 |
November 24, 2017 |
February 1, 2017 |
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Mayo Clinic - Jacksonville
Jacksonville, Florida, United States - Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, United States - (and 66 more...)
|
| 47 |
NCT00075439 |
Completed |
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 6 more...)
|
- Drug: gefitinib
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients progression-free at 6 months
- Incidence of adverse events graded according to NCI CTCAE version 3.0
- Confirmed tumor response to treatment will be evaluated and will be considered a PR or CR on consecutive evaluations at least 4 weeks apart
- (and 4 more...)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT00075439 |
NCI-2012-02796
MC0279
N01CM62205 |
|
December 2003 |
May 2007 |
|
January 12, 2004 |
June 4, 2013 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 48 |
NCT00655655 |
Completed |
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 17 more...)
|
- Drug: everolimus
- Drug: vatalanib
- Other: pharmacological study
- (and 3 more...)
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)
- Toxicity associated with everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)
- Therapeutic antitumor activity of everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)
- (and 4 more...)
|
96 |
All |
18 Years and older (Adult, Senior) |
NCT00655655 |
MC0414
NCI-2009-01200
P30CA015083 |
|
December 2004 |
September 15, 2009 |
January 11, 2018 |
April 10, 2008 |
January 17, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 49 |
NCT00654160 |
Completed |
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer |
- Anal Cancer
- Carcinoma of the Appendix
- Colorectal Cancer
- (and 9 more...)
|
- Drug: fluorouracil
- Drug: irinotecan hydrochloride
- Drug: leucovorin calcium
- (and 2 more...)
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
|
- Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy
- Response rate of genotype-based dosing in the subset of patients that has colorectal cancer
|
7 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00654160 |
CDR0000592931
P30CA015083
MC064G
NCI-2009-01216 |
|
June 2008 |
November 2010 |
December 3, 2012 |
April 7, 2008 |
May 25, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 50 |
NCT00454363 |
Completed
Has Results |
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer |
- Gastrin-Producing Neuroendocrine Tumor
- Lung Carcinoid Tumor
- Metastatic Digestive System Neuroendocrine Tumor G1
- (and 8 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Pazopanib Hydrochloride
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
- Plasma Trough Level of GW786034
- Progression Free Survival (PFS)
- Change in Tumor Blood Flow Assessed by Functional CT
|
52 |
All |
21 Years and older (Adult, Senior) |
NCT00454363 |
NCI-2009-00201
CDR0000537034
MDACC 2006-0077
7650
N01CM62202
P30CA016672
U01CA062490 |
|
March 2007 |
March 2014 |
December 2014 |
March 30, 2007 |
November 18, 2015 |
April 1, 2015 |
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - M D Anderson Cancer Center
Houston, Texas, United States
|
Create an RSS feed from your search for:
Download the search results for: